---
title: "Fulcrum Therapeutics' Greg Tourangeau to Depart; Sapir, Musso and Oltmans Receive Retention Payments"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289511356.md"
description: "Fulcrum Therapeutics announced that Greg Tourangeau will depart as Vice President, Finance and principal accounting officer by mutual agreement. Concurrently, the company agreed to retention payments for CEO Alex Sapir, CFO Alan Musso, and Chief Legal Officer Curtis Oltmans. These measures aim to preserve capital following the discontinuation of pociredir development. The executive agreements include enhanced Change in Control benefits."
datetime: "2026-06-11T20:33:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289511356.md)
  - [en](https://longbridge.com/en/news/289511356.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289511356.md)
---

# Fulcrum Therapeutics' Greg Tourangeau to Depart; Sapir, Musso and Oltmans Receive Retention Payments

**Fulcrum Therapeutics agreed to retention payments for Alex C. Sapir, Alan Musso and Curtis Oltmans and announced that Greg Tourangeau will depart as Vice President, Finance and principal accounting officer.**

Individual

Alex C. Sapir

Alan Musso

Curtis Oltmans

Greg Tourangeau

Role

President and Chief Executive Officer

Chief Financial Officer

Chief Legal Officer and Head of External Affairs

Vice President, Finance and principal accounting officer

Type of Change

Employment agreement amended; retention payment and enhanced Change in Control benefits

Employment agreement amended; retention payment and enhanced Change in Control benefits

Employment agreement amended; retention payment and enhanced Change in Control benefits

Departure agreed

Effective Date

June 5, 2026 (amendment); retention payable upon Change in Control or qualifying termination

June 11, 2026 (amendment); retention payable upon Change in Control or qualifying termination

June 5, 2026 (amendment); retention payable upon Change in Control or qualifying termination

June 10, 2026 (agreement to depart; actual departure date to be agreed)

Reason

Restructuring-related retention to preserve capital after discontinuation of pociredir development

Restructuring-related retention to preserve capital after discontinuation of pociredir development

Restructuring-related retention to preserve capital after discontinuation of pociredir development

Mutual agreement; not due to any disagreement over accounting or financial reporting

Replacement Info

Not disclosed

Not disclosed

Not disclosed

To be agreed between Mr. Tourangeau and Fulcrum Therapeutics

Background Details

President and CEO; employment agreement filed as Exhibit 10.18 to 2025 10-K

Chief Financial Officer; employment agreement filed as Exhibit 10.19 to 2025 10-K

Chief Legal Officer and Head of External Affairs; employment agreement filed as Exhibit 10.20 to 2025 10-K

Vice President, Finance and principal accounting officer; departure mutually agreed

Board/Committee Role Changes

Not disclosed

Not disclosed

Not disclosed

Not disclosed

Original SEC Filing: Fulcrum Therapeutics, Inc. \[ FULC \] - 8-K - Jun. 11, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [FULC.US](https://longbridge.com/en/quote/FULC.US.md)

## Related News & Research

- [Fulcrum CFO Alan Musso takes over as principal accounting officer after Tourangeau exit](https://longbridge.com/en/news/295409058.md)
- [Nvidia is a massive investor in the genius artificial intelligence (AI) stock up 170% this year](https://longbridge.com/en/news/295183287.md)
- [Prairie Operating Extends Anniversary Warrant Deadlines to Aug. 14 in High Trail Amendment](https://longbridge.com/en/news/295411664.md)
- [The Bull Case For Southern (SO) Could Change Following Major Convertible Note Issuance And Stronger Earnings](https://longbridge.com/en/news/295701848.md)
- [Dan Ives says we're in the "3rd inning" of the AI revolution. Is Nvidia stock still a buy after the pullback?](https://longbridge.com/en/news/295298135.md)